Meanwhile, tumor DNA methylation profiling that was concurrently done with DST for this patient (15, data not shown) would have also discouraged the use of temozolomide, which revealed an absence of methylation of the promoter for MGMT, encoding 6-O-methylguanine-DNA methyltransferase, that predicts temozolomide resistance (54). This evidence concerns the gene MGMT and neoplasm.